They’re a leader in medical image processing and analysis with their lead product Texrad – a software instrument for analysing medical images, in particular looking at cancer deposits in the Liver.
Riddell tells Proactive: ”All imaging nowadays is digital and this software … has become a very impressive research tool for increasing the diagnostic specificity of image analysis of livers with tumour deposits”.
”We will be developing new products that look at chest and lung cancer”.
Riddell adds: ”This is undoubtedly an exciting time for Texrad … the growth and interest in what it’s doing, the increasing publications that we’re getting, the recognition it’s achieving and I think the potential it has for general adoption – not just by research scientists but by general radiological practitioners – should give us a much larger revenue growth in the future”.
Story by ProactiveInvestors